In this weeks video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back to the myeloma community.
The BOTTOM LINE: The Myeloma Warrior Spirit means having the energy and resilience to seek out the best care for patients.
David Siegel, MD
John Theurer Cancer Center
Hackensack, New Jersey, USA
A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
RRMM patients refractory to proteasome inhibitors and immunomodulatory drugs (IMiD) have a very poor outcome. PD-L1 expressed on most MM plasma cells is a potential mechanism of immune evasion. MK-3475 is a potent, highly selective, humanized IgG4/kappa isotype, anti-PD-1 monoclonal antibody designed to block PD-1 interaction with PD-L1 and PD-L2, enhancing lymphocytic activity, tumor regression and immune rejection.
Visit our website at: http://www.myeloma.org
Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma.
Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma.
The IMWG Conference Series "Making Sense of
57th ASH Annual Meeting | Dec. 7, 2015
Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma
In this weeks video, Dr. Brian G.M. Durie explains which criteria and tests determine if a patients myeloma is smoldering or active.
Only treat myeloma if test results are absolutely clear and show active disease.
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better understand sustained MRD-negativity.
The BOTTOM LINE: MRD-negative status is great for a myeloma patient to have, but it still does not mean the patient is cured.
In this weeks video, Dr. Brian G.M. Durie explains why myeloma patients should discuss the use of supplements with their doctors.
?Stop unnecessary supplements that may have harmful side effects or may interfere with ongoing myeloma treatments.
In this video, Dr. Brian G.M. Durie explains that second transplant and certain novel therapies may work well for early relapse of myeloma.
Many options are available in cases of early relapse, including second transplant or the use of novel therapy combinations.
In this weeks video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly dosing of carfilzomib.
BOTTOM LINE: Ensure your doctor is aware of the ARROW study in order to consider once-weekly dosing of carfilzomib.